Guided Therapeutics (GTHP) Cash from Financing Activities (2011 - 2025)
Guided Therapeutics (GTHP) reported Cash from Financing Activities of $267000.0 for Q4 2025, down 49.24% on a YoY basis from $526000.0 in Q4 2024, and up 47.51% sequentially from $181000.0 in Q3 2025.
Guided Therapeutics (GTHP) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Cash from Financing Activities data on file, last reported at $267000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 49.24% year-over-year to $267000.0; the trailing twelve-month figure through Dec 2025 stood at $745000.0 (down 18.67% YoY), and the FY2025 full-year result was $745000.0, down 18.67% from the prior year.
- Cash from Financing Activities rose to $267000.0 in Q4 2025, from $181000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $2.9 million in Q3 2022 to a low of -$154000.0 in Q3 2023.
- A 5-year average of $346600.0 and a median of $188500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 687.88% in 2022 and slumped 300.0% in 2024, its largest moves.
- Tracing GTHP's Cash from Financing Activities over 5 years: stood at -$53000.0 in 2021, then rose by 20.75% to -$42000.0 in 2022, then surged by 566.67% to $196000.0 in 2023, then jumped by 168.37% to $526000.0 in 2024, then sank by 49.24% to $267000.0 in 2025.
- Business Quant data shows GTHP's Cash from Financing Activities at $267000.0 in Q4 2025, $181000.0 in Q3 2025, and $239000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Dec 31, 2025 | 267,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 239,000.00 |
| Jun 30, 2025 | 239,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Sep 30, 2023 | -154,000.00 |
| Sep 30, 2023 | -154,000.00 |